Skip to main content
    A

    Alto Neuroscience, Inc. (ANRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $22.65
    +0.94 (+4.33%)

    Market Cap: $851.95M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(7/11)
    Avg Surprise
    -37.37%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.70
    Range$-0.89 - $-0.60
    7 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.80+12.0%
    60d ago$-0.80+12.0%
    30d ago$-0.700.0%
    7d ago$-0.700.0%
    Current$-0.70
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.94
    Range$-1.35 - $-0.63
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.94---
    Sep 26EST
    		-$-0.70---
    Jun 26
    Reported Aug 12
    		$-0.65$-0.71+8.45%Beat+0.0%
    Mar 26
    Reported May 13
    		$-0.80$-0.50-60.00%Miss-42.9%
    Dec 25
    Reported Mar 16
    		$-0.45$-0.66+31.82%Beat+13.5%
    Sep 25
    Reported Nov 12
    		$-0.52$-0.64+18.75%Beat+16.1%
    Jun 25
    Reported Aug 13
    		$-0.65$-0.60-8.33%Miss-8.3%
    Mar 25
    Reported May 14
    		$-0.56$-0.62+9.68%Beat+26.3%
    Dec 24
    Reported Mar 20
    		$-0.52$-0.55+5.45%Beat+93.3%
    Sep 24
    Reported Nov 12
    		$-0.62$-0.64+3.13%Beat-
    Jun 24
    Reported Aug 13
    		$-0.60$-0.67+10.45%Beat-
    Mar 24
    Reported May 14
    		$-0.76$-0.46-65.22%Miss-
    Dec 23
    Reported Feb 5
    		$-7.77$-1.67-365.27%Miss-

    Key Metrics

    Valuation
    P/E Ratio-9.36EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-49.20%ROIC-27.22%
    Financial Health
    Debt/Equity0.09xInterest Coverage-36.26x
    Current Ratio14.85xQuick Ratio14.85x
    Trading Statistics
    Beta1.34Avg Volume706.15K
    52-Week High$37.4852-Week Low$5.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$23.50
    SMA 20$25.60
    SMA 50$30.14
    SMA 200$23.91
    EMA 10$23.68
    EMA 20$25.48
    EMA 50$27.70
    EMA 200$23.58

    MACD

    Line: -2.25Signal: -2.08Hist: -0.17

    ADX

    ADX: 43.2+DI: 11.4-DI: 27.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$25.03

    Bollinger Bands

    Upper Band$30.96
    Lower Band$20.24
    %B Position4187%(Upper)
    Band Width0.23

    RSI (14-Day)

    Oversold
    29.2

    Momentum Oscillators

    Stoch %K9.0
    Stoch %D9.6
    Williams %R-79.3
    ROC (10d)-10.5%
    Momentum-2.66
    CCI (20d)-102.3
    MFI (14d)11.7

    Volatility Measures

    ATR (14d)$1.69(7.5%)
    StdDev (20d)2.68
    Hist Vol53.9%(High)

    Volume Flow

    VWAP$22.53
    OBV94.3M
    AD Line25.5M
    CMF (20d)-0.411

    Volume Metrics

    Avg Vol (20d)728.8K
    Vol Ratio0.7x
    VWMA (20d)$25.59

    Pivot Points

    R3$23.70
    R2$23.14
    R1$22.43
    Pivot Point$21.87
    S1$21.16
    S2$20.60
    S3$19.89

    Advanced Oscillators

    TSI-46.78
    Ultimate Osc34.0
    KST-262.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$394,000$0$0$0$372,000$0
    Cost of RevenueN/A$184,000$157,000$164,000$100,000$171,000$170,000$200,000$100,000$97,000$92,000$95,000
    Gross ProfitN/A$-184,000$-157,000$-164,000$-100,000$-171,000$-170,000$-200,000$-100,000$-97,000$-92,000$-467,000
    Operating Expenses$29.13M$26.95M$-115,673,000$14.95M$18.58M$15.68M$16.83M$18.89M$18.34M$14.29M$11.67M$9.72M
    R&D$22.11M$20.29M$12.00M$10.53M$13.12M$9.97M$10.80M$13.06M$13.18M$9.95M$9.64M$7.97M
    SG&A$7.02M$6.84M$5.06M$4.43M$5.56M$5.70M$6.20M$5.83M$5.16M$4.43M$2.12M$1.75M
    Operating Income$-29,129,000$-27,138,000$115.67M$-14,951,000$-18,682,000$-15,676,000$-16,997,000$-18,886,000$-18,341,000$-14,386,000$-11,765,000$-9,718,000
    Interest Income$2.11M$1.56M$1.56M$1.53M$1.68M$1.83M$2.13M$2.50M$2.66M$1.56M$738,000$714,000
    Interest Expense$491,000$545,000$575,000$650,000$646,000$598,000$333,000$349,000$347,000$346,000$356,000$363,000
    Income Before Tax$-27,638,000$-26,237,000$-16,182,000$-14,181,000$-17,706,000$-15,169,000$-15,201,000$-16,783,000$-16,030,000$-13,417,000$-11,217,000$-9,141,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-1$0$-363,000$363,000
    Net Income$-27,638,000$-26,237,000$-16,182,000$-14,181,000$-17,706,000$-15,169,000$-15,201,000$-16,783,000$-16,030,000$-13,417,000$-11,217,000$-9,141,000
    EBITDA$-26,963,000$-25,508,000$-15,450,000$-13,367,000$-16,960,000$-14,400,000$-14,698,000$-16,312,000$-15,570,000$-12,974,000$-10,769,000$-8,715,000
    EBIT$-27,147,000$-25,692,000$-15,607,000$-13,531,000$-17,060,000$-14,571,000$-14,868,000$-16,434,000$-15,683,000$-13,071,000$-10,861,000$-8,778,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANRO

    News

    Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold (NYSE:ANRO)

    Alto Neuroscience is focusing its pipeline on ALTO-207 for treatment-resistant depression after mixed results from ALTO-101 and delays for other candidates. While ALTO-207 aims for superior efficacy...

    Seeking Alpha•10/15/26•Bearish

    Here's Why You Should Add ANRO Stock to Your Portfolio Now

    Alto Neuroscience (ANRO) is a clinical-stage biopharmaceutical company focused on developing precision psychiatry medicines for mental health disorders, including depression, bipolar depression...

    TradingView•10/14/26•Bullish

    Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

    Alto Neuroscience, Inc. has promoted Nick Smith to President and Chief Financial Officer, effective August 26, 2026. Smith will continue to lead finance and oversee corporate strategy and business development...

    The National Law Review•10/12/26•Bullish

    Alto Neuroscience Inc. Stock Grades | ANRO

    This article provides detailed stock information for Alto Neuroscience Inc. (ANRO), a clinical-stage biopharmaceutical company. It includes analyst ratings, key financial metrics such as market value, EPS, and volume...

    Barron's•10/10/26•Neutral

    Alto Neuroscience Inc. Advanced Charts | ANRO

    This article provides advanced chart data and company information for Alto Neuroscience Inc. (ANRO). It details key financial metrics, analyst ratings, stock performance data...

    Barron's•10/10/26•Neutral

    ANRO Valuation and Fair Value

    P/E
    -9.4x
    P/B
    4.4x
    See GNG's fair value

    ANRO Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -27.2%
    ROE
    -49.2%

    ANRO Competitors

    CompanyTicker
    Jade Biosciences, Inc.JBIO
    Cullinan Oncology LLCCGEM
    Si-Bone IncSIBN
    Monte Rosa Therapeutics IncGLUE
    Kura Oncology IncKURA
    InMode LtdINMD
    Rigel Pharmaceuticals IncRIGL
    P3 Health Partners IncPIII

    Sector: Healthcare

    ANRO Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    0
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ANRO Bull Case vs Bear Case

    Bull case

    • ANRO beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 90.9% of ANRO's analyst ratings are Buy or Strong Buy.

    ANRO Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    1.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.70
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About ANRO

    Does ANRO pay dividends?

    Alto Neuroscience, Inc. (ANRO) does not currently pay a regular dividend.

    What is ANRO's market cap?

    Alto Neuroscience, Inc. (ANRO) has a market capitalization of $851.95M with a current stock price of $22.65.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In